Dynamics of measurable residual disease for risk stratification and guiding allogeneic transplant in acute myeloid leukaemia patients with myelodysplasia‐related mutations in first remission
British Journal of Haematology · 2025
DOI: 10.1111/bjh.19917 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2025. Verfasst von Ling Jiang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Clinical Decision-Making, Hematopoietic Stem Cell Transplantation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Accurate classification and risk prediction are critical for therapeutic decision‐making in patients with acute myeloid leukaemia (AML). Myelodysplasia‐related (MR) gene mutations are classified as adverse genetic factors by the European LeukaemiaNet‐2022 guidelines. However, their prognostic value in de novo AML remains controversial. This study retrospectively analysed 188 patients with de novo AML‐MR, stratifying them into four subgroups based on dynamic measurable residual disease (MRD) after induction, one or two courses of consolidation chemotherapy. The median follow‐up was 36.8 months (4.6–73.7). Patients with persistent or recurrent MRD positivity after the second consolidation had the poorest 3‐year relapse‐free survival (RFS), overall survival (OS) and cumulative incidence of relapse compared to the other groups ( p < 0.001). Multivariable analysis identified this high‐risk group as an independent risk factor for both RFS and OS. We observed significant heterogeneity of OS benefit from allogeneic stem cell transplantation (allo‐SCT) by MRD‐risk groups, with substantial OS advantage for patients in subgroup D (3‐year OS: allo‐SCT 70.0% vs. 18.2% without, p < 0.001) but no benefit for others ( p = 0.047 for interaction). This study underscores the importance of dynamic MRD in refining risk stratification and identifying de novo AML patients with MR mutations who would benefit from allo‐SCT during the first complete remission.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China.
- Department of Hematology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
ORCID-Profile: Ling Jiang, Xuejie Jiang
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
- National Natural Science Foundation of China
Zitieren
APA
Jiang, L., Cheng, J., Sun, J., Zhang, Y., Wu, Q., Huang, Y., Long, Z., Yan, P., & Jiang, X. (2025). Dynamics of measurable residual disease for risk stratification and guiding allogeneic transplant in acute myeloid leukaemia patients with myelodysplasia‐related mutations in first remission. British Journal of Haematology. https://doi.org/10.1111/bjh.19917
Vancouver
Jiang L, Cheng J, Sun J, Zhang Y, Wu Q, Huang Y, et al. Dynamics of measurable residual disease for risk stratification and guiding allogeneic transplant in acute myeloid leukaemia patients with myelodysplasia‐related mutations in first remission. British Journal of Haematology. 2025. doi:10.1111/bjh.19917
BibTeX
@article{Jiang2025,
author = {Jiang, Ling and Cheng, Jiaying and Sun, Junya and Zhang, Yujiao and Wu, Quan and Huang, Yun and Long, Zhiquan and Yan, Ping and Jiang, Xuejie},
title = {Dynamics of measurable residual disease for risk stratification and guiding allogeneic transplant in acute myeloid leukaemia patients with myelodysplasia‐related mutations in first remission},
journal = {British Journal of Haematology},
year = {2025},
doi = {10.1111/bjh.19917}
}
EUVIMED